Group items matching

in title, tags, annotations or url

The ASPEN Rhoads Research Foundation, the philanthropic arm of the American Society for Parenteral and Enteral Nutrition, is dedicated to improving patient care by advancing the science and practice of clinical nutrition and metabolism. Founded in 1976, ASPEN is an interdisciplinary organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With more than sixty-five hundred members from around the world, ASPEN is a community of dietitians, nurses, pharmacists, physicians, scientists, students, and other health professionals from every facet of nutrition support clinical practice, research, and education. To advance its mission, the foundation is accepting applications for its ASPEN Rhoads Research Foundation Grants program. Through the annual program, grants of up to $25,000 will be awarded for research projects by early-career investigators focused on clinical nutrition and metabolic support in alignment with the priorities outlined in the ASPEN Research Agenda.

1. Basic Science of Gene Therapy for Hemophilia * Basic science, tropism, transduction efficiency & tolerability of Adeno associated virus (AAV) * AAV antibody seroprevalence, titer- assessment, reduction & tolerance * Role of immunosuppression in managing immune response and potential retreatment * Effect of Gene Therapy on liver biology 2. Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies * Basic biology of TFPI interactions with Protein C, ATIII & Protein S * Cross talk among regulators (e.g., Protein S being a co-factor for both Protein C and TFPI) * Role of different TFPI pools in regulation of coagulation * Impact of concomitant treatments (especially antifibrinolytics) added to anti-TFPI on the physiology of hemostasis * Note: Pfizer will not supply study drug 3. Burden of disease: Clinical Hemophilia A and B * Natural history of hemophilia and adherence to current standard of care * Arthropathy: presence, development, clinical burden & joint damage in hemophilia * Patient experiences with hemophilia, treatment preferences and quality of care * Quality of Life/Work analysis and cost of care in Hemophilia

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.